牛牛AI助理已提取核心訊息
On January 29, 2024, 60 Degrees Pharmaceuticals, Inc., a Delaware-based company, entered into an Underwriting Agreement with WallachBeth Capital LLC for a public offering of 5,260,901 units at $0.385 per unit and 999,076 pre-funded units at $0.375 per pre-funded unit. The offering included common stock and warrants, with the warrants exercisable immediately and expiring five years from the date of issuance. The underwriters were granted an over-allotment option, which was partially exercised on January 31, 2024, for additional warrants. The offering closed on January 31, 2024, with net proceeds of approximately $1.9 million after underwriting discounts, commissions, and offering expenses. The proceeds are intended for capitalization, financial flexibility, and the relaunch of the company's malaria prevention project in the U.S. Company officers and directors have agreed not to sell or dispose of any common stock until July 29, 2024, without WallachBeth Capital LLC's consent. The offering was made under the company's Registration Statement on Form S-1, declared effective by the SEC on January 29, 2024.
On January 29, 2024, 60 Degrees Pharmaceuticals, Inc., a Delaware-based company, entered into an Underwriting Agreement with WallachBeth Capital LLC for a public offering of 5,260,901 units at $0.385 per unit and 999,076 pre-funded units at $0.375 per pre-funded unit. The offering included common stock and warrants, with the warrants exercisable immediately and expiring five years from the date of issuance. The underwriters were granted an over-allotment option, which was partially exercised on January 31, 2024, for additional warrants. The offering closed on January 31, 2024, with net proceeds of approximately $1.9 million after underwriting discounts, commissions, and offering expenses. The proceeds are intended for capitalization, financial flexibility, and the relaunch of the company's malaria prevention project in the U.S. Company officers and directors have agreed not to sell or dispose of any common stock until July 29, 2024, without WallachBeth Capital LLC's consent. The offering was made under the company's Registration Statement on Form S-1, declared effective by the SEC on January 29, 2024.
2024年1月29日，總部位於特拉華州的公司60 Degrees Pharmicals, Inc. 與WallachBeth Capital LLC簽訂了承保協議，以每單位0.385美元的價格公開發行5,260,901套單位，以每單位0.385美元的價格公開發行999,076個預先籌資單位。此次發行包括普通股和認股權證，認股權證可立即行使，自發行之日起五年內到期。承銷商獲得了額外認股權證的超額配股權，該期權已於2024年1月31日部分行使。此次發行於2024年1月31日結束，扣除承保折扣、佣金和發行費用後的淨收益約爲190萬美元。所得款項用於資本化、財務靈活性以及公司在美國重啓的瘧疾預防項目。未經WallachBeth Capital LLC的同意，公司高管和董事已同意，在2024年7月29日之前不出售或處置任何普通股。此次發行是根據該公司在S-1表格上的註冊聲明進行的，美國證券交易委員會於2024年1月29日宣佈生效。
2024年1月29日，總部位於特拉華州的公司60 Degrees Pharmicals, Inc. 與WallachBeth Capital LLC簽訂了承保協議，以每單位0.385美元的價格公開發行5,260,901套單位，以每單位0.385美元的價格公開發行999,076個預先籌資單位。此次發行包括普通股和認股權證，認股權證可立即行使，自發行之日起五年內到期。承銷商獲得了額外認股權證的超額配股權，該期權已於2024年1月31日部分行使。此次發行於2024年1月31日結束，扣除承保折扣、佣金和發行費用後的淨收益約爲190萬美元。所得款項用於資本化、財務靈活性以及公司在美國重啓的瘧疾預防項目。未經WallachBeth Capital LLC的同意，公司高管和董事已同意，在2024年7月29日之前不出售或處置任何普通股。此次發行是根據該公司在S-1表格上的註冊聲明進行的，美國證券交易委員會於2024年1月29日宣佈生效。
有用
沒用